Success Stories: NAILG Achieves EB1A Approval for Researcher Advancing Immunotherapy and Vaccine Science

Client’s Testimonial:

“NAILG was incredibly responsive in communication—they guided me on how to prepare materials, helped organize them thoroughly, and got my EB-1A approved in just 1 year. Their efficiency was impressive!”

On January 15^th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Scientist in the field of Biomedical Science (Approval Notice).

General Field: Biomedical Science

Position at the Time of Case Filing: Research Scientist

Country of Origin: China

Country of Residence at the Time of Filing: China

Approval Notice Date: January 15^th, 2025

Processing Time: 1 year, 4 days

Case Summary:

When the world faces new infectious diseases, the search for more effective vaccines and immune therapies becomes a race against time. At the heart of this scientific frontier is our client, a biomedical researcher whose work has redefined how scientists understand immune response and vaccine development. Her discoveries, bridging molecular immunology and therapeutic innovation, have now earned her EB1A (Alien of Extraordinary Ability) approval through the skilled representation of North America Immigration Law Group (NAILG).

From the beginning of her career, she has focused on one fundamental question: how can the immune system be guided to fight disease more effectively? Her answer has come through years of groundbreaking work that unraveled how immune molecules influence inflammation, infection, and cancer. By revealing the mechanisms that control these interactions, she has opened the door to a new generation of vaccines designed not only to prevent disease but also to improve treatment outcomes.

As one expert described:

“[Client]’s work in studying immune responses, together with her novel vaccine development and testing, is incredibly vital in combating infections. Her work has illustrated how to use new findings surrounding immune responses to design and tailor more productive vaccines.”

Her studies have been published in top-tier journals, where her findings have been cited more than 2,811 times by researchers worldwide. Her body of work, comprising 47 peer-reviewed publications, has guided investigations into how inflammation contributes to diseases ranging from bacterial infections to cancer.

What distinguishes our client’s research is its translation from theory to practice. Her studies have inspired applications in vaccine design, cancer immunology, and autoimmune disease management. By identifying molecular targets that regulate inflammation, she has paved the way for vaccines that generate stronger, longer-lasting immune protection. She has conducted 48 reviews for journals, which has solidified her reputation as a leader in global biomedical research.

As she continues her work in the United States, our client is positioned to play a key role in advancing vaccine science and immunological research, ensuring that her groundbreaking contributions continue to serve global and national public health priorities. Her EB1A approval stands as both a testament to her scientific excellence and to NAILG’s commitment to highlighting the extraordinary impact of leading researchers on the future of medicine.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Tens of Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.